High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Background: Patients with primary sclerosing cholangitis ( PSC ) and inflammatory bowel disease ( IBD ) have a high risk of developing colorectal cancer and dysplasia. Ursodeoxycholic acid ( UDCA ) has been suggested to have chemopreventive effects on the development of colorectal cancer and dysplasia but long‐term data and larger trials are lacking. Aim: To evaluate the effect of high dose (17–23 mg/kg/day) UDCA on colorectal neoplasia in a cohort of patients with PSC and IBD . Methods: From our previous 5‐year randomised controlled trial of UDCA vs. placebo in PSC , we performed a follow‐up of 98 patients with concomitant IBD from entry of the trial 1996–1997 until 2009 for development of colorectal cancer or dysplasia. Results: The total follow‐up time was 760 person‐years. Dysplasia/cancer‐free survival was compared between placebo‐ ( n = 50) and UDCA ‐treated ( n = 48) patients. There was a similar frequency of dysplasia or cancer after 5 years between patients originally assigned to UDCA or placebo (13% vs. 16%) and no difference in dysplasia/cancer‐free survival ( P = 0.46, log rank test). At the end of 2009 no difference in cancer‐free survival was detected, 30% of the placebo patients compared with 27% of UDCA patients had developed colorectal cancer or dysplasia. Conclusions: Long‐term high dose ursodeoxycholic acid does not prevent colorectal cancer or dysplasia in patients with primary sclerosing cholangitis ‐associated inflammatory bowel disease .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394
Self-citationPhase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence
Alberts, D. S., Martínez, M. E., Hess, L. M., Einspahr, J. G., Green, S. B., Bhattacharyya, A. K., Guillen, J., Krutzsch, M., Batta, A. K., Salen, G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji144 · Cited by 247 · cited 1×
“have shown that a low dose of UDCA 8–10 mg/kg prevented recurrence of adenomas.(19) Another recent study demonstrated that the use of very high dose UDCA 28–30 mg/kg/day was associated with increased risk of colorectal dysplasia and cancer in patients with UC and PSC.”
Result
Cited by
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.038 · Cited by 533
Self-citationRole of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citation
Metadata
- Authors
- Lindström, L., Boberg, K. M., Wikman, O., Friis‐Liby, I., Hultcrantz, R., Prytz, H., Sandberg‐Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., Gangsøy‐Kristiansen, M., Danielsson, Å., & Bergquist, A.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-01-05
- Volume
- 35
- Issue
- 4
- Pages
- 451-457
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2020569486
- Cited by
- 84
- References
- 4
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04966.x
- The paper
- Lindström, L., Boberg, K. M., Wikman, O., Friis‐Liby, I., Hultcrantz, R., Prytz, H., Sandberg‐Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., Gangsøy‐Kristiansen, M., Danielsson, Å., & Bergquist, A. (2012). High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04966.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.